Loading
A phase 3 trial of Sacituzumab tirumotecan, Vinflunine and Docetaxel in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) is a phase 3 interventional study registered as NCT07419295 by Merck Sharp & Dohme LLC, with 590 participants planned, started 2026-04-23 and due to reach its primary completion in 2029-07-27. Interventions recorded: Sacituzumab tirumotecan, Vinflunine, Docetaxel, Paclitaxel, Rescue medications for sacituzumab tirumotecan and Rescue medications for chemotherapy.
Shares Muscle-invasive and advanced bladder cancer, Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD) and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Docetaxel, Bladder & urothelial cancer and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.